L3VLUP
ProSign in

TECH in the 13F filings

Bio-techne Corp · CUSIP 09073M104

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q3 2026 · early filersQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Q3 2026: 5 of 95 managers have filed so far; the filing deadline is 16 November 2026. Its figures cover those filers only, so it is not yet a picture of the tracked managers.

Quarter end
30 Sep 2026
the date the book describes
Filed
9 Nov 2026
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
5
filed both Q2 2026 and Q3 2026; 0 listed it in both
Shares listed
612,119
combined, among listed positions
Reported value
$44m
combined, at the quarter end

Among the 5 comparable managers: 1 buyer (opened or added shares) and 0 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +520,851.

Managers listing TECH in Q3 2026

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2026, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
Squarepoint Ops LLC612,119$44munder 0.1%Added+520,8519 Nov 2026 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2026 to Q3 2026, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
8 in Q4 2024 to 1 in Q3 2026

Tracked managers listing it, at least.

0102030201620182020202220242026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
TECH by quarter
QuarterHoldersReported valueBuyersSellers
Q3 20142$912kn.a.n.a.
Q4 20146$132mn.a.n.a.
Q1 20156$157mn.a.n.a.
Q2 20153$123mn.a.n.a.
Q3 20157$162mn.a.n.a.
Q4 20154$154mn.a.n.a.
Q1 20165$161mn.a.n.a.
Q2 20165$321mn.a.n.a.
Q3 20164$202mn.a.n.a.
Q4 20163$197mn.a.n.a.
Q1 20174$222mn.a.n.a.
Q2 20175$359mn.a.n.a.
Q3 20175$361mn.a.n.a.
Q4 20175$435mn.a.n.a.
Q1 20189$693mn.a.n.a.
Q2 20187$611mn.a.n.a.
Q3 201811$1.2bnn.a.n.a.
Q4 201810$873mn.a.n.a.
Q1 201913$1.2bnn.a.n.a.
Q2 201912$1.5bnn.a.n.a.
Q3 201911$1.4bnn.a.n.a.
Q4 201911$1.5bnn.a.n.a.
Q1 202014$1.2bnn.a.n.a.
Q2 20208$1.4bnn.a.n.a.
Q3 202014$1.2bnn.a.n.a.
Q4 202010$1.2bnn.a.n.a.
Q1 202111$1.5bnn.a.n.a.
Q2 20216$1.4bnn.a.n.a.
Q3 20218$1.5bnn.a.n.a.
Q4 20219$1.9bnn.a.n.a.
Q1 20227$1.3bnn.a.n.a.
Q2 202213$1.3bnn.a.n.a.
Q3 202213$1.0bnn.a.n.a.
Q4 20229$954mn.a.n.a.
Q1 202315$896mn.a.n.a.
Q2 202310$1.2bnn.a.n.a.
Q3 202310$960mn.a.n.a.
Q4 202310$1.2bn65
Q1 20248$1.2bn53
Q2 20247$1.4bn35
Q3 202410$2.1bn46
Q4 20248$1.7bn44
Q1 20258$1.2bn63
Q2 20258$860m56
Q3 202514$1.4bn113
Q4 202513$1.7bn1620
Q1 202610$1.6bn1717
Q2 202621$2.6bn2418
Q3 20261$44m10

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

TECH and GILD →TECH and AMGN →TECH and ARGX →Choose a stock to compare with TECH →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own TECH, latest filings →Back to the 13F Explorer →